That gap can cause withdrawal effects , rebound appetite, and setbacks in your progress
Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, Vujacic-Mirski K, Helmstdter J, Krller-Schn S, Mnzel T, Daiber A
TRIUMPH-4 reported in December 2025
This article is exclusive to STAT+ subscribers Unlock this article plus daily intelligence on Capitol Hill and the life sciences industry by subscribing to STAT+
When BxPC-3 cells were treated with the drug formulations, an increase in scratch area was noted in the ORI@Lipo (ORI 5 g/mL), ORI@CPD-Lipo (ORI 5 g/mL), and ORI@CPD-Lipo plus CKAAKN (ORI 5 g/mL) groups compared to the control, indicating that the drug-loaded liposomes suppressed BxPC-3 cell migration
up to 4 per day